{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:21:01Z","timestamp":1786119661886,"version":"build-2736575974"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,9]]},"DOI":"10.1097\/wnf.0b013e3181f0ed9a","type":"journal-article","created":{"date-parts":[[2010,9,1]],"date-time":"2010-09-01T08:16:34Z","timestamp":1283328994000},"page":"250-253","source":"Crossref","is-referenced-by-count":28,"title":["Effects of Zonisamide in the Treatment of Alcohol Dependence"],"prefix":"10.1097","volume":"33","author":[{"given":"Gabriel","family":"Rubio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"L\u00f3pez-Mu\u00f1oz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Ferre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Mart\u00ednez-Gras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo","family":"Ponce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 M.","family":"Pascual","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel A.","family":"Jim\u00e9nez-Arriero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilio","family":"Alamo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-8-20210203","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.euroneuro.2005.04.005","article-title":"Alcohol use disorders in EU countries and Norway: an overview of the epidemiology.","volume":"15","author":"Rehm","year":"2005","journal-title":"Eur Neuropsychopharmacol"},{"key":"R2-8-20210203","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1093\/alcalc\/36.5.419","article-title":"Naltrexone versus acamprosate: 1 year follow-up alcohol dependence treatment.","volume":"36","author":"Rubio","year":"2001","journal-title":"Alcohol Alcoholism"},{"issue":"suppl 1","key":"R3-8-20210203","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1080\/10550490190942489","article-title":"Update on anticonvulsants for the treatment of alcohol withdrawal.","volume":"10","author":"Malcolm","year":"2001","journal-title":"Am J Addict"},{"key":"R4-8-20210203","doi-asserted-by":"crossref","first-page":"135","DOI":"10.2174\/1874473710902020135","article-title":"Review of topiramate: an antiepileptic for the treatment of alcohol dependence.","volume":"2","author":"Kenna","year":"2009","journal-title":"Curr Drug Abuse Rev"},{"key":"R5-8-20210203","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1111\/j.1530-0277.1997.tb03733.x","article-title":"A double-blind, placebo-controlled pilot study of carbamazepine for the treatment of alcohol dependence.","volume":"21","author":"Mueller","year":"1997","journal-title":"Alcohol Clin Exp Res"},{"key":"R6-8-20210203","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1001\/archpsyc.62.1.37","article-title":"Efficacy of valproate maintenance in patients with bipolar disorder and alcoholism: a double-blind placebo-controlled study.","volume":"62","author":"Salloum","year":"2005","journal-title":"Arch Gen Psychiatry"},{"key":"R7-8-20210203","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.1399-5618.2006.00292.x","article-title":"Effects of lamotrigine in patients with bipolar disorder and alcohol dependence.","volume":"8","author":"Rubio","year":"2006","journal-title":"Bipolar Disord"},{"key":"R8-8-20210203","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1055\/s-2004-815473","article-title":"Effects of topiramate in the treatment of alcohol dependence.","volume":"37","author":"Rubio","year":"2004","journal-title":"Pharmacopsychiatry"},{"key":"R9-8-20210203","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1001\/jama.298.14.1641","article-title":"Topiramate for treating alcohol dependence: a randomized controlled trial.","volume":"298","author":"Johnson","year":"2007","journal-title":"JAMA"},{"key":"R10-8-20210203","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1111\/j.1530-0277.2008.00680.x","article-title":"Using topiramate or naltrexone for the treatment of alcohol-dependent patients.","volume":"32","author":"Florez","year":"2008","journal-title":"Alcohol Clin Exp Res"},{"key":"R11-8-20210203","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1002\/hup.833","article-title":"High and low dosage oxcarbazepine versus naltrexone for the prevention of relapse in alcohol-dependent patients.","volume":"22","author":"Martinotti","year":"2007","journal-title":"Hum Psychopharmacol Clin Exp"},{"key":"R12-8-20210203","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1517\/13543784.15.6.637","article-title":"New antiepileptic drugs that are second generation to existing antiepileptic drugs.","volume":"15","author":"Bialer","year":"2006","journal-title":"Exp Opin Invest Drugs"},{"issue":"suppl 2","key":"R13-8-20210203","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.eplepsyres.2005.11.004","article-title":"Introduction to zonisamide.","volume":"68","author":"Baulac","year":"2006","journal-title":"Epilepsy Res"},{"key":"R14-8-20210203","doi-asserted-by":"crossref","first-page":"347","DOI":"10.2165\/00023210-200519040-00010","article-title":"Zonisamide. A review of its use in the management of partial seizures in epilepsy.","volume":"19","author":"Frampton","year":"2005","journal-title":"CNS Drugs"},{"key":"R15-8-20210203","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1517\/17425255.4.4.493","article-title":"Zonisamide: review of pharmacology, clinical efficacy, tolerability, and safety.","volume":"4","author":"Kothare","year":"2008","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"R16-8-20210203","doi-asserted-by":"crossref","first-page":"139","DOI":"10.2165\/00023210-200923020-00004","article-title":"Role of antiepileptic drugs in the management of eating disorders.","volume":"23","author":"McElroy","year":"2009","journal-title":"CNS Drugs"},{"key":"R17-8-20210203","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1080\/00952990903060150","article-title":"The anticonvulsant zonisamide reduces ethanol self-administration by risky drinkers.","volume":"35","author":"Sarid-Segal","year":"2009","journal-title":"Am J Drug Alcohol Abuse"},{"key":"R21-8-20210203","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1111\/j.1360-0443.1989.tb00737.x","article-title":"Assessment of alcohol withdrawal: the revised Clinical Institute Withdrawal Assessment for Alcohol Scale (CIWA-AR).","volume":"84","author":"Sullivan","year":"1989","journal-title":"Br J Addict"},{"issue":"suppl 1","key":"R22-8-20210203","first-page":"44","article-title":"Validacion de la escala de la intensidad de la dependencia alcoholica.","volume":"5","author":"Rubio","year":"1998","journal-title":"Psiquiatr Biol"},{"key":"R23-8-20210203","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1111\/j.1360-0443.1988.tb00485.x","article-title":"Reliability of a timeline method: assessing normal drinkers' reports of recent drinking and a comparative evaluation across several populations.","volume":"83","author":"Sobell","year":"1998","journal-title":"Br J Addict"},{"key":"R26-8-20210203","first-page":"207","article-title":"Medications and alcohol craving.","volume":"23","author":"Swift","year":"1999","journal-title":"Alcohol Res Health"},{"key":"R27-8-20210203","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.pbb.2007.04.001","article-title":"Zonisamide decreases ethanol intake in rats and mice.","volume":"87","author":"Knapp","year":"2007","journal-title":"Pharmacol Biochem Behav"},{"key":"R28-8-20210203","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/nrn1430","article-title":"The neurobiology of antiepileptic drugs.","volume":"5","author":"Rogawski","year":"2004","journal-title":"Nat Rev Neurosci"},{"key":"R29-8-20210203","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1097\/wnf.0b013e3180413d7d","article-title":"Clinical pharmacology and mechanism of action of zonisamide.","volume":"30","author":"Biton","year":"2007","journal-title":"Clin Neuropharmacol"},{"key":"R30-8-20210203","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1016\/j.addbeh.2005.12.029","article-title":"An overview of medications for the treatment of alcohol withdrawal and alcohol dependence with an emphasis on the use of older and newer anticonvulsants.","volume":"31","author":"Ait-Daoud","year":"2006","journal-title":"Addict Behav"},{"issue":"suppl 1","key":"R31-8-20210203","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1111\/j.1528-1157.2000.tb06047.x","article-title":"Topiramate as an inhibitor of carbonic anhydrase isoenzymes.","volume":"41","author":"Dodgson","year":"2000","journal-title":"Epilepsia"},{"key":"R32-8-20210203","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1093\/chemse\/25.3.277","article-title":"Psychophysical and neurobiological evidence that the oral sensation elicited by carbonated water is of chemogenic origin.","volume":"25","author":"Dessirier","year":"2000","journal-title":"Chem Senses"},{"key":"R33-8-20210203","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1111\/j.1742-1241.2007.01365.x","article-title":"Adjunctive zonisamide for treatment refractory anxiety.","volume":"61","author":"Kinrys","year":"2007","journal-title":"Int J Clin Pract"},{"key":"R34-8-20210203","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/0306-3623(87)90016-4","article-title":"Neuropharmacology of zonisamide, a new antiepileptic drug.","volume":"18","author":"Hammond","year":"1987","journal-title":"Gen Pharmacol"}],"container-title":["Clinical Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00002826-201009000-00008","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:41:39Z","timestamp":1786041699000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00002826-201009000-00008"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,9]]},"references-count":29,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2010]]}},"URL":"https:\/\/doi.org\/10.1097\/wnf.0b013e3181f0ed9a","relation":{},"ISSN":["0362-5664"],"issn-type":[{"value":"0362-5664","type":"print"}],"subject":[],"published":{"date-parts":[[2010,9]]}}}